Trial
NCT04504032
A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Gates Medical Research Institute
Collaborators
—
Condition
COVID-19
Intervention
Rivaroxaban
Why stopped
Based on Data Monitoring Committee''s recommendation on 3 February 2021, the study was stopped on 4 February 2021 due to futility.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-10-22